Evaluating and treating small cell lung cancer

SCLC accounts for less than 15% of newly diagnosed lung cancers and can be distinguished from NSCLC by a high cell turnover rate and a rapidly progressive disease course, with a median survival of 3 months without treatment in extensive disease

by Dr Alexandra Leary and Dr Mary O'Brien

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content. View our subscription and registration options.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us



  • Limited free articles a month 
  • Free email bulletins

Register Now

Take a 30-day trial

  • Join MIMS now and pay nothing for the first 30 days

Sign Up